Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding Ltd (OP: RHHBF ) 335.00 +17.75 (+5.59%) Streaming Delayed Price Updated: 3:57 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roche Holding Ltd < Previous 1 2 3 4 5 6 7 Next > Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy March 15, 2022 Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... Via Benzinga Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial February 18, 2022 Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... Via Benzinga Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests February 03, 2022 Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH Via Benzinga Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues February 02, 2022 Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year, Via Benzinga Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab February 01, 2022 Biogen Inc (NASDAQ: BIIB) has Via Benzinga FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo January 31, 2022 The FDA has approved Genentech's, a unit of Via Benzinga Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months January 25, 2022 The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (... Via Benzinga CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply January 12, 2022 The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild... Via Benzinga Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases December 20, 2021 Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)... Via Benzinga Novartis Launches New Share Buyback Program Of Up To $15B December 16, 2021 Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth... Via Benzinga After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial December 15, 2021 Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape... Via Benzinga Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients December 14, 2021 Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen... Via Benzinga Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings December 13, 2021 Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60%... Via Benzinga Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial December 10, 2021 Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).... Via Benzinga Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer December 10, 2021 Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus... Via Benzinga Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19 December 07, 2021 The European Commission has extended the marketing authorization for Roche Holdings AG's (OTC: RHHBY) Actemra/RoActemra (Tocilizumab) to treat patients with severe... Via Benzinga Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients December 06, 2021 Immunocore Holdings Plc (NASDAQ: IMCR) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid... Via Benzinga Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests December 03, 2021 President Biden announced that private health insurance plans would soon reimburse people who buy over-the-counter (OTC), at-home rapid tests for COVID-19. What Happened... Via Benzinga Exposures COVID-19 Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact December 02, 2021 Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY... Via Benzinga Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer November 19, 2021 The European Commission (EC) has granted conditional marketing authorization to Roche Holdings AG's (OTC: RHHBY) Gavreto (pralsetinib) for treating adults... Via Benzinga Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? November 18, 2021 Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... Via Benzinga Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes November 18, 2021 Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced data from its Phase 1/2 trial of SPK-8011 in hemophilia A. At a median efficacy follow-up of 33.4... Via Benzinga Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill November 17, 2021 Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month... Via Benzinga Exposures COVID-19 Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail November 12, 2021 The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and... Via Benzinga Exposures COVID-19 EU Regulator Backs Regeneron-Roche's COVID-19 Drug November 11, 2021 The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc... Via Benzinga Exposures COVID-19 Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters November 10, 2021 With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition.... Via Benzinga ALX Oncology Falls After Updated Data For Solid Tumors Candidate November 09, 2021 ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/... Via Benzinga Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose November 08, 2021 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg... Via Benzinga Exposures COVID-19 Novartis To Offload Its Stake Back To Roche For $20.7B November 04, 2021 Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting... Via Benzinga Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting November 02, 2021 Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in... Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.